Form D · Biotechnology
Agilis Biotherapeutics, Inc.
Cambridge, MA · CIK 0001595971
Offering snapshot reported Feb 24, 2017 · SEC filing
- Reported sold
- $12.7M Offering amount: $23.3M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 15, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 24, 2017 | Initial | $12,668,727 | No comparison | 19 | SEC filing |
| Feb 2, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 8, 2014 | Initial | $8,000,000 | No comparison | 27 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-281302
Source: Form D, filed Feb 24, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| G. Houston Hall | Director |
| Robert Hardie | Director |
| Mark J. Pykett | Director, Executive |
| Ian Ratcliffe | Director |
| Alexander M. Seaver | Director |
| Adrian Z. Stecyk | Director |
| Arthur Tzianabos | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
245 First Street Suite 1800
Cambridge, MA, 02142
Cambridge, MA, 02142